DEAL RELEASE / PRESSEMITTEILUNGEN
9 June, 2026
Read time: 3 min
McDermott Will & Schulte has advised Servier, an independent international pharmaceutical group governed by a foundation, on the agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX), a biopharmaceutical company focused on developing innovative therapies for serious muscle disorders.
This acquisition supports Servier’s strategic ambition in rare neurology for patients with high unmet medical needs.
The transaction represents total value of up to $2.65 billion.
The transaction is subject to regulatory clearance and customary closing conditions and is expected to close in the third quarter of 2026.
The McDermott Will & Schulte team involved in the transaction -alongside the Servier legal team including Benoit Cheron, Nicolas Mavel, Barbara Theofilopoulou-Le-Louarn, Gabrielle Rochecouste- comprised :
In Paris :
- Emmanuelle Trombe, partner, Natacha Vasak, Caroline Noyrez, associates, on Life Sciences aspects
In Bruxelles :
- Axel Schultz, partner, on Antitrust aspects
In Chicago :
- Andrew Warmus, Ann Marie Brodarick, partners, Ari Banks, Lily Wang, associates, on Corporate aspects
Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,700+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.
